Omeros Sees Unusually Large Options Volume (NASDAQ:OMER)

Omeros Corporation (NASDAQ:OMER) saw some unusual options trading activity on Wednesday. Investors acquired 7,487 call options on the company. This represents an increase of approximately 54% compared to the typical volume of 4,876 call options.

Analyst Upgrades and Downgrades

Several research firms have issued reports on OMER. HC Wainwright lifted their price target on shares of Omeros from $20.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Wall Street Zen lowered shares of Omeros from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Omeros in a research report on Thursday, January 22nd. Finally, D. Boral Capital restated a “buy” rating and set a $36.00 target price on shares of Omeros in a research report on Tuesday, January 27th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $40.33.

Insider Buying and Selling at Omeros

In other Omeros news, CAO David J. Borges sold 30,000 shares of the company’s stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $12.31, for a total value of $369,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 12.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Corient Private Wealth LLC grew its holdings in Omeros by 13.0% in the fourth quarter. Corient Private Wealth LLC now owns 688,025 shares of the biopharmaceutical company’s stock valued at $11,817,000 after purchasing an additional 79,263 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in Omeros in the 4th quarter valued at approximately $159,000. Invesco Ltd. grew its holdings in Omeros by 26.8% during the 4th quarter. Invesco Ltd. now owns 154,782 shares of the biopharmaceutical company’s stock valued at $2,658,000 after buying an additional 32,707 shares during the last quarter. Virtus Investment Advisers LLC purchased a new position in Omeros during the fourth quarter worth $450,000. Finally, Wellington Management Group LLP raised its holdings in shares of Omeros by 4.2% in the fourth quarter. Wellington Management Group LLP now owns 202,617 shares of the biopharmaceutical company’s stock worth $3,480,000 after acquiring an additional 8,170 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

Key Omeros News

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: Q4 results showed a swing to GAAP net income of $86.5M ($1.22/share) vs. a loss a year earlier; full-year 2025 loss narrowed materially — this reversal to profitability supports the rally. Business Wire Release
• Positive Sentiment: Omeros reported EPS of $3.14 for the quarter, well above analyst expectations (consensus around -$0.55), a significant beat that likely drove short-term buying. MarketBeat EPS Report
• Positive Sentiment: Management announced YARTEMLEA is expected to be financially self-sustaining in 2026 and reiterated a goal of positive company-level cash flow in 2027, improving visibility on funding needs. Seeking Alpha: YARTEMLEA Outlook
• Positive Sentiment: After-hours reporting of a Novo Nordisk-related deal windfall and continued optimism around drug launches added to sentiment that near-term cash and milestone income could be stronger than feared. MSN: Novo Nordisk Deal
• Neutral Sentiment: Earnings call transcript and highlights provide more detail on strategic deals, FDA pathways and commercialization plans — useful for modeling but already priced in by some traders. Earnings Call Transcript
• Neutral Sentiment: Market technicals: the stock recently moved above its 200-day moving average, a signal that may attract technical buyers but not a fundamental guarantee. Technical Note
• Neutral Sentiment: Short-form earnings snapshots and sector articles summarize the quarter and management commentary — helpful for headlines but add limited new info beyond the press release and call. Yahoo Finance Highlights

Omeros Stock Up 15.3%

NASDAQ:OMER traded up $1.61 on Wednesday, reaching $12.17. 2,446,460 shares of the company’s stock were exchanged, compared to its average volume of 1,486,050. The firm has a market capitalization of $863.07 million, a price-to-earnings ratio of -6.01 and a beta of 2.45. Omeros has a 52-week low of $2.95 and a 52-week high of $17.65. The business has a fifty day moving average of $11.40 and a 200-day moving average of $9.76.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.